EP1140903B1
(en)
*
|
1998-12-23 |
2004-08-04 |
Eli Lilly And Company |
Aromatic amides
|
DE10023486C1
(de)
*
|
2000-05-09 |
2002-03-14 |
Schering Ag |
Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
|
DE10023484A1
(de)
*
|
2000-05-09 |
2001-11-22 |
Schering Ag |
Anthranylamide und deren Verwendung als Arzneimittel
|
DE10023485A1
(de)
*
|
2000-05-09 |
2001-11-22 |
Schering Ag |
Anthranylalkyl- und -cycloalkylamide und deren Verwendung als Arzneimittel
|
CN1234358C
(zh)
|
2000-06-21 |
2006-01-04 |
弗·哈夫曼-拉罗切有限公司 |
苯并噻唑衍生物
|
CA2430951A1
(en)
*
|
2000-12-07 |
2002-06-13 |
Cv Therapeutics, Inc. |
Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
|
US7105682B2
(en)
*
|
2001-01-12 |
2006-09-12 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US7102009B2
(en)
|
2001-01-12 |
2006-09-05 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US20020147198A1
(en)
*
|
2001-01-12 |
2002-10-10 |
Guoqing Chen |
Substituted arylamine derivatives and methods of use
|
US20030134836A1
(en)
|
2001-01-12 |
2003-07-17 |
Amgen Inc. |
Substituted arylamine derivatives and methods of use
|
RU2322981C2
(ru)
|
2001-02-19 |
2008-04-27 |
Новартис Аг |
Комбинация и способ предупреждения рака молочной железы
|
US6864255B2
(en)
|
2001-04-11 |
2005-03-08 |
Amgen Inc. |
Substituted triazinyl amide derivatives and methods of use
|
WO2002090349A1
(de)
*
|
2001-05-08 |
2002-11-14 |
Schering Aktiengesellschaft |
N-oxidanthranylamid-derivate und deren verwendung als arzneimittel
|
DE10123573B4
(de)
*
|
2001-05-08 |
2005-06-02 |
Schering Ag |
N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel
|
DE50213703D1
(de)
*
|
2001-05-08 |
2009-09-03 |
Bayer Schering Pharma Ag |
Selektive anthranylamidpyridinamide als vegfr-2 und vegfr-3 inhibitoren
|
DK1387838T3
(da)
*
|
2001-05-08 |
2006-08-14 |
Schering Ag |
Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
|
DE10123587B4
(de)
*
|
2001-05-08 |
2005-04-07 |
Schering Ag |
Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel
|
PT1392313E
(pt)
|
2001-05-16 |
2007-07-17 |
Novartis Ag |
Combinação que compreende n - ( 5- [ 4- ( metil-piperazinomrtil ) - benxoilamido ] - 2 -metilfenil ) - 4 -( 3 - piridil ) - 2 - pirimidina-amina e um agente quimioterapêutico
|
JPWO2002100833A1
(ja)
*
|
2001-06-12 |
2004-09-24 |
住友製薬株式会社 |
Rhoキナーゼ阻害剤
|
TWI315982B
(en)
|
2001-07-19 |
2009-10-21 |
Novartis Ag |
Combinations comprising epothilones and pharmaceutical uses thereof
|
WO2003030902A1
(en)
|
2001-10-09 |
2003-04-17 |
Tularik Inc. |
Imidazole derivates as anti-inflammatory agents
|
GB0126902D0
(en)
*
|
2001-11-08 |
2002-01-02 |
Novartis Ag |
Organic compounds
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
JP5227492B2
(ja)
|
2002-05-16 |
2013-07-03 |
ノバルティス アーゲー |
癌におけるedgレセプター結合剤の使用
|
US7307088B2
(en)
*
|
2002-07-09 |
2007-12-11 |
Amgen Inc. |
Substituted anthranilic amide derivatives and methods of use
|
US7094789B2
(en)
|
2002-07-22 |
2006-08-22 |
Asahi Kasei Pharma Corporation |
5-substituted isoquinoline derivatives
|
DE10235690A1
(de)
*
|
2002-07-31 |
2004-02-19 |
Schering Ag |
VEGFR-2 und VEGFR-3 inhibitorische Anthranylamidpyridinamide
|
US7615565B2
(en)
|
2002-07-31 |
2009-11-10 |
Bayer Schering Pharma Aktiengesellschaft |
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
|
US7338956B2
(en)
|
2002-08-07 |
2008-03-04 |
Sanofi-Aventis Deutschland Gmbh |
Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
|
EP1388341A1
(en)
*
|
2002-08-07 |
2004-02-11 |
Aventis Pharma Deutschland GmbH |
Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
|
CA2508914A1
(en)
|
2002-12-04 |
2004-06-17 |
Gene Logic Inc. |
Modulators of melanocortin receptor
|
US7696225B2
(en)
|
2003-01-06 |
2010-04-13 |
Osi Pharmaceuticals, Inc. |
(2-carboxamido)(3-Amino) thiophene compounds
|
TWI299664B
(en)
|
2003-01-06 |
2008-08-11 |
Osi Pharm Inc |
(2-carboxamido)(3-amino)thiophene compounds
|
US7087761B2
(en)
|
2003-01-07 |
2006-08-08 |
Hoffmann-La Roche Inc. |
Cyclization process for substituted benzothiazole derivatives
|
WO2004069792A2
(en)
*
|
2003-02-03 |
2004-08-19 |
Janssen Pharmaceutica N.V. |
Quinoline-derived amide modulators of vanilloid vr1 receptor
|
JP4909068B2
(ja)
|
2003-02-14 |
2012-04-04 |
グラクソ グループ リミテッド |
カルボキサミド誘導体
|
EP1602647B1
(en)
|
2003-03-07 |
2013-10-16 |
Santen Pharmaceutical Co., Ltd. |
Novel compound having 4-pyridylalkylthio group as substituent
|
JP4944613B2
(ja)
|
2003-05-19 |
2012-06-06 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
免疫抑制化合物および組成物
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
WO2004108133A2
(en)
*
|
2003-06-05 |
2004-12-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of vr1 receptor
|
DE10327719A1
(de)
*
|
2003-06-13 |
2005-01-20 |
Schering Ag |
VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone
|
US7202260B2
(en)
|
2003-06-13 |
2007-04-10 |
Schering Ag |
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
|
WO2006074147A2
(en)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics, Inc. |
Nitrogen containing bicyclic compounds and therapeutical use thereof
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
US7691886B2
(en)
|
2003-07-11 |
2010-04-06 |
Merck Patent Gmbh |
Benzimidazole derivatives as raf kinase inhibitors
|
GB0326601D0
(en)
*
|
2003-11-14 |
2003-12-17 |
Novartis Ag |
Organic compounds
|
UA89035C2
(ru)
|
2003-12-03 |
2009-12-25 |
Лео Фарма А/С |
Эфиры гидроксамовых кислот и их фармацевтическое применение
|
PL1717229T3
(pl)
|
2004-02-17 |
2011-11-30 |
Santen Pharmaceutical Co Ltd |
Nowy cykliczny związek mający grupę 4-pirydyloalkilotiolową z wprowadzoną do niej (nie)podstawioną grupą aminową
|
EP1568368A1
(en)
*
|
2004-02-26 |
2005-08-31 |
Schering Aktiengesellschaft |
Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor
|
DE102004009238A1
(de)
*
|
2004-02-26 |
2005-09-08 |
Merck Patent Gmbh |
Arylamid-Derivate
|
WO2005085188A2
(en)
*
|
2004-03-02 |
2005-09-15 |
Compass Pharmaceuticals Llc |
Compounds and methods for anti-tumor therapy
|
DE102004011720B4
(de)
*
|
2004-03-10 |
2008-04-03 |
Bayer Schering Pharma Aktiengesellschaft |
Radiohalogenierte Benzamidderivate und deren Verwendung in der Tumordiagnostik und Tumortherapie
|
US7427390B2
(en)
*
|
2004-03-10 |
2008-09-23 |
Schering Ag |
Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy
|
CN1956983B
(zh)
|
2004-05-24 |
2010-05-26 |
弗·哈夫曼-拉罗切有限公司 |
4-羟基-4-甲基-哌啶-1-甲酸(4-甲氧基-7-吗啉-4-基-苯并噻唑-2-基)-酰胺
|
DE102004039876A1
(de)
*
|
2004-06-23 |
2006-01-26 |
Lanxess Deutschland Gmbh |
Herstellung von fluorierten 1,3-Benzodioxanen
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
WO2006032631A1
(en)
|
2004-09-22 |
2006-03-30 |
Janssen Pharmaceutica N.V. |
Inhibitors of the interaction between mdm2 and p53
|
EP1655295A1
(en)
*
|
2004-11-03 |
2006-05-10 |
Schering Aktiengesellschaft |
Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
|
EP1655297A1
(en)
*
|
2004-11-03 |
2006-05-10 |
Schering Aktiengesellschaft |
Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
|
US7906533B2
(en)
|
2004-11-03 |
2011-03-15 |
Bayer Schering Pharma Ag |
Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
|
EP1657241A1
(en)
|
2004-11-03 |
2006-05-17 |
Schering Aktiengesellschaft |
Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
|
WO2006048172A1
(en)
|
2004-11-05 |
2006-05-11 |
F. Hoffmann-La Roche Ag |
Process for preparation of isonicotinic acid derivatives
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
EP1854787B1
(en)
*
|
2005-03-03 |
2010-09-01 |
Santen Pharmaceutical Co., Ltd. |
Novel cyclic compound having quinolylalkylthio group
|
CA2602444C
(en)
|
2005-03-23 |
2013-03-19 |
F.Hoffmann-La Roche Ag |
Acetylenyl-pyrazolo-pyrimidine derivatives as mglur2 antagonists
|
US7906511B2
(en)
|
2005-03-31 |
2011-03-15 |
Santen Pharmaceutical Co., Ltd. |
Cyclic compound having pyrimidinylalkylthio group
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
BRPI0616571A2
(pt)
|
2005-09-27 |
2011-06-21 |
Hoffmann La Roche |
oxadiazolil pirazol-piridiminas como antagonistas de mglur2, processo para sua preparação, composição farmacêutica que os contém e uso dos mesmo
|
AR058065A1
(es)
|
2005-09-27 |
2008-01-23 |
Novartis Ag |
Compuestos de carboxiamina y uso de los mismos.composiciones farmaceuticas.
|
US8247556B2
(en)
*
|
2005-10-21 |
2012-08-21 |
Amgen Inc. |
Method for preparing 6-substituted-7-aza-indoles
|
AU2006314444C1
(en)
|
2005-11-21 |
2018-01-04 |
Novartis Ag |
Neuroendocrine tumor treatment using mTOR inhibitors
|
BRPI0619208A2
(pt)
*
|
2005-11-30 |
2011-09-20 |
Astellas Pharma Inc |
derivado de 2-aminobenzamida c07d 307/14 c07d 307/22 c07d 309/14 c07d 319/12 c07d 401/12 c07d 405/12 c07d 413/12 c07d 417/12
|
AU2007228782B2
(en)
|
2006-03-22 |
2012-09-06 |
Janssen Pharmaceutica N.V. |
Inhibitors of the interaction between MDM2 and p53
|
CA2644649C
(en)
|
2006-03-22 |
2014-06-17 |
Janssen Pharmaceutica N.V. |
Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53
|
CN101415409B
(zh)
|
2006-04-05 |
2012-12-05 |
诺瓦提斯公司 |
用于治疗癌症的治疗剂的组合
|
WO2007128820A1
(en)
|
2006-05-09 |
2007-11-15 |
Novartis Ag |
Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
|
GB0612721D0
(en)
|
2006-06-27 |
2006-08-09 |
Novartis Ag |
Organic compounds
|
BRPI0717564A2
(pt)
|
2006-09-29 |
2013-10-22 |
Novartis Ag |
Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
|
WO2008077809A1
(en)
*
|
2006-12-22 |
2008-07-03 |
F. Hoffmann-La Roche Ag |
Process for the manufacture of 7-oxa-bicyclo derivatives
|
KR101475540B1
(ko)
|
2007-01-29 |
2014-12-22 |
산텐 세이야꾸 가부시키가이샤 |
혈관 신생 저해 활성을 갖는 신규 옥사디아졸 유도체 및 티아디아졸 유도체
|
AU2008216327A1
(en)
|
2007-02-15 |
2008-08-21 |
Novartis Ag |
Combination of LBH589 with other therapeutic agents for treating cancer
|
EP1975166A1
(en)
*
|
2007-03-30 |
2008-10-01 |
Bayer Schering Pharma AG |
Synthesis of anthranilamides
|
TW200922557A
(en)
|
2007-08-06 |
2009-06-01 |
Janssen Pharmaceutica Nv |
Substituted phenylenediamines as inhibitors of the interaction between MDM2 and p53
|
PT2260020E
(pt)
|
2008-03-26 |
2014-10-28 |
Novartis Ag |
Inibidores das desacetilases b baseados no hidroxamato
|
AR073216A1
(es)
|
2008-08-27 |
2010-10-20 |
Leo Pharma As |
Derivados de piridina como receptor de vegfr-2 e inhibidores de proteina tirosina quinasa y uso farmaceutico de los mismos
|
WO2010043050A1
(en)
|
2008-10-16 |
2010-04-22 |
Celator Pharmaceuticals Corporation |
Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
|
CA2747558A1
(en)
|
2008-12-18 |
2010-07-15 |
Novartis Ag |
New salts
|
IL294514A
(en)
|
2008-12-18 |
2022-09-01 |
Novartis Ag |
1-[4-[1[(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid mipomarate salt
|
WO2010071794A1
(en)
|
2008-12-18 |
2010-06-24 |
Novartis Ag |
New polymorphic form of 1- (4- { l- [ (e) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
|
ES2396023T3
(es)
|
2009-01-29 |
2013-02-18 |
Novartis Ag |
Bencimidazoles sustituidos para el tratamiento de astrocitomas
|
CN102307868B
(zh)
|
2009-02-04 |
2016-06-22 |
詹森药业有限公司 |
作为抗癌剂的吲哚衍生物
|
AU2010264698C1
(en)
|
2009-06-26 |
2013-05-16 |
Novartis Ag |
1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP 17
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
JP5781510B2
(ja)
|
2009-08-12 |
2015-09-24 |
ノバルティス アーゲー |
ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
|
PT2467141T
(pt)
|
2009-08-17 |
2019-02-06 |
Intellikine Llc |
Compostos heterocíclicos e suas utilizações
|
EP2467383A1
(en)
|
2009-08-20 |
2012-06-27 |
Novartis AG |
Heterocyclic oxime compounds
|
BR112012008075A2
(pt)
|
2009-08-26 |
2016-03-01 |
Novartis Ag |
compostos de heteroarila tetrassubstituídos e seu uso como moduladores de mdm2 e/ou mdm4
|
KR20120093867A
(ko)
|
2009-09-10 |
2012-08-23 |
아이알엠 엘엘씨 |
비시클릭 헤테로아릴의 에테르 유도체
|
WO2011054828A1
(en)
|
2009-11-04 |
2011-05-12 |
Novartis Ag |
Heterocyclic sulfonamide derivatives useful as mek inhibitors
|
US20120289501A1
(en)
|
2009-11-25 |
2012-11-15 |
Novartis Ag |
Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
|
AU2012265844A1
(en)
|
2009-12-08 |
2013-05-02 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
JP5456908B2
(ja)
|
2009-12-08 |
2014-04-02 |
ノバルティス アーゲー |
ヘテロ環式スルホンアミド誘導体
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
WO2011157787A1
(en)
|
2010-06-17 |
2011-12-22 |
Novartis Ag |
Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
EP2582681A1
(en)
|
2010-06-17 |
2013-04-24 |
Novartis AG |
Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
CA2841142C
(en)
|
2010-06-23 |
2020-12-15 |
Ryan D. Morin |
Biomarkers for non-hodgkin lymphomas and uses thereof
|
KR102061353B1
(ko)
|
2010-09-10 |
2020-01-02 |
에피자임, 인코포레이티드 |
인간 ezh2의 억제제 및 이의 사용 방법
|
US9175331B2
(en)
|
2010-09-10 |
2015-11-03 |
Epizyme, Inc. |
Inhibitors of human EZH2, and methods of use thereof
|
WO2012035078A1
(en)
|
2010-09-16 |
2012-03-22 |
Novartis Ag |
17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
|
US20130324526A1
(en)
|
2011-02-10 |
2013-12-05 |
Novartis Ag |
[1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
AU2012223448B2
(en)
|
2011-02-28 |
2017-03-16 |
Epizyme, Inc. |
Substituted 6,5-fused bicyclic heteroaryl compounds
|
JP2014507465A
(ja)
|
2011-03-08 |
2014-03-27 |
ノバルティス アーゲー |
フルオロフェニル二環式ヘテロアリール化合物
|
JO3438B1
(ar)
|
2011-04-13 |
2019-10-20 |
Epizyme Inc |
مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
|
TW201733984A
(zh)
|
2011-04-13 |
2017-10-01 |
雅酶股份有限公司 |
經取代之苯化合物
|
EA023064B1
(ru)
|
2011-04-28 |
2016-04-29 |
Новартис Аг |
ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
|
US8859535B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
US8859586B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
ES2691650T3
(es)
|
2011-09-15 |
2018-11-28 |
Novartis Ag |
3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
|
US8969341B2
(en)
|
2011-11-29 |
2015-03-03 |
Novartis Ag |
Pyrazolopyrrolidine compounds
|
CA2859869A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
CA2859862A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
EP2794589A1
(en)
|
2011-12-23 |
2014-10-29 |
Novartis AG |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
CN104136429A
(zh)
|
2011-12-23 |
2014-11-05 |
诺华股份有限公司 |
用于抑制bcl2与结合配偶体相互作用的化合物
|
KR20140107574A
(ko)
|
2011-12-23 |
2014-09-04 |
노파르티스 아게 |
Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
|
CN102603729A
(zh)
*
|
2012-01-12 |
2012-07-25 |
贵州大学 |
N-(2-(取代苯并噻唑-2-氨基甲酰基)-取代苯基)吡啶甲酰胺类衍生物
|
US8815926B2
(en)
|
2012-01-26 |
2014-08-26 |
Novartis Ag |
Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
|
US9725427B2
(en)
|
2012-03-16 |
2017-08-08 |
Biohaven Pharmaceutical Holding Company Limited |
Prodrugs of riluzole and their method of use
|
MX371119B
(es)
|
2012-04-03 |
2020-01-17 |
Novartis Ag |
Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
|
ES2745016T3
(es)
|
2012-04-13 |
2020-02-27 |
Epizyme Inc |
Bromhidrato de N-((4,6-dimetil-2-oxo-L,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[L,1'-bifenil]-3-carboxamida para su uso en el tratamiento de un trastorno proliferativo celular del sistema hematológico
|
JP6171003B2
(ja)
|
2012-05-24 |
2017-07-26 |
ノバルティス アーゲー |
ピロロピロリジノン化合物
|
EP3628662A1
(en)
|
2012-10-15 |
2020-04-01 |
Epizyme, Inc. |
Substituted benzene compounds
|
EP2948451B1
(en)
|
2013-01-22 |
2017-07-12 |
Novartis AG |
Substituted purinone compounds
|
WO2014115080A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
|
EP2968340A4
(en)
|
2013-03-15 |
2016-08-10 |
Intellikine Llc |
COMBINING KINASE INHIBITORS AND USES THEREOF
|
CN103130696B
(zh)
*
|
2013-03-21 |
2014-06-11 |
山东大学 |
邻氨基苯甲酰胺类化合物及其制备方法与应用
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
CN103405434A
(zh)
*
|
2013-08-22 |
2013-11-27 |
中国药科大学 |
Vegfr-2抑制剂及其用途
|
PE20161273A1
(es)
|
2013-10-16 |
2016-12-18 |
Epizyme Inc |
Forma salina de hidrocloruro para la inhibicion de ezh2
|
CN104163794A
(zh)
*
|
2013-10-17 |
2014-11-26 |
中国药科大学 |
2-氨基芳环类血管内皮生长因子受体(vegfr)抑制剂及其制备方法和用途
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
EP3174869B1
(en)
|
2014-07-31 |
2020-08-19 |
Novartis AG |
Combination therapy of a met inhibitor and an egfr inhibitor
|
CA3079076A1
(en)
|
2017-10-18 |
2019-04-25 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Methods and compounds for improved immune cell therapy
|
AU2017444054B2
(en)
|
2017-12-21 |
2021-10-07 |
Hefei Institutes Of Physical Science, Chinese Academy Of Sciences |
Class of pyrimidine derivative kinase inhibitors
|
EP4058465A1
(en)
|
2019-11-14 |
2022-09-21 |
Cohbar Inc. |
Cxcr4 antagonist peptides
|
US11091447B2
(en)
|
2020-01-03 |
2021-08-17 |
Berg Llc |
UBE2K modulators and methods for their use
|
CN117479935A
(zh)
*
|
2021-04-19 |
2024-01-30 |
上海药苑生物科技有限公司 |
用于治疗川崎病的苯并噻唑和喹啉衍生物
|